Immunoglobulin support for patients with hematologic malignancies: when should you discuss starting, how should you dose, and when is it safe to consider stopping.
Immunoglobulin support for patients with hematologic malignancies: when should you discuss starting, how should you dose, and when is it safe to consider stopping.
November 6 @ 18:00 - 19:00 EST
Join us for the ultimate Immunoglobulin update for your secondary hypogammaglobulinemia patients—because sometimes even B cells need a little backup.
Speakers:
Jeannie Callum, BA, MD, FRCPC – GROUP O NEGATIVE
Director of Transfusion Medicine, Kingston Health Sciences Centre. Professor, Department of Pathology and Molecular Medicine, Queen’s University
Abi Vijenthira, MD, SM, FRCPC
Hematologist, Princess Margaret Cancer Centre
Adil Adatia, MD, FRCPC
Assistant Professor, Department of Medicine, University of Alberta
Zoe McQuilten, MD
Professor, School of Public Health and Preventive Medicine, Monash University.
Erica Wood, MD
Head, Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University. Haematologist, Monash Health, both in Melbourne, Australia
Guido Lancman, MD
Clinical Researcher and Assistant Professor
University Health Network, Princess Margaret Hospital and University of Toronto
Kathryn Webert, MD, FRCPC
Medical Director and Special Advisor, Canadian Blood Services
Learning Objectives:
1. Discuss the evidence from clinical trials for IVIG and SCIG for patients with hematologic malignancies and secondary hypogammaglobulinemia
2. Estimate the cost of 1 year of IVIG or SCIG for the healthcare system
3. Understand the evidence gap to be addressed by the RATIONAL-PT and IRIS trials
Accreditation: This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours. Certificates of Attendance will be sent to all CHS members who participate.
This webinar is supported by a grant from Grifols and the CHS Scientific Planning Committee has planned it to achieve scientific integrity, objectivity and balance.
Target Audience: Hematologists, Trainees
Conflicts of Interest: Funded grants or clinical trials. Speakers bureaus, honoaria
Name of for-profit or not-for-profit organization(s) : Canadian Blood Services, Abbvie, Amgen, AstraZeneca, Beigene, BMS, CSL Behring, Gilead, Janssen, Novartis, Roche, Sanofi, SOBI, Takeda, Octapharma